Antitumor Effect of Oleoyl-siRNA against Pancreatic Cancer Using a Portal Vein Infusion Liver-Metastatic Mouse Model
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Takanori Kubo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Cell Biology, Department of Life Science, Faculty of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, RNA, Small Interfering, Liver Neoplasms, Portal Vein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Toray Research Center, Tsuchiya Memorial Medical Foundation.
Abstract (Originalsprache)
In this study, we developed an oleoyl-siRNA conjugate in which oleic acid was conjugated at the 5'-end of the sense strand of the siRNA. Furthermore, we examined the effects of RNAi in a mouse model of pancreatic cancer with liver metastasis. The mouse model of pancreatic cancer with liver metastasis was developed by implanting Sui67Luc human pancreatic cancer cells into the portal veins of mice. Sui67Luc cells have high expression of tumor-related genes such as β-catenin, vascular endothelial growth factor, and programmed cell death ligand-1. All genes were knocked down using siRNA, among which siRNA targeting β-catenin exhibited the most suitable RNAi effect. Therefore, we investigated the in vitro RNAi effect of oleoyl-siRNA (Ole-siRNA) targeting the β-catenin gene in Sui67Luc cells and found that it was stronger than that of unmodified siRNA. For in vivo experiments, we investigated the biodistribution, antitumor effect, and change in life expectancy of mice upon systemic administration of Ole-siRNA complexed with Invivofectamine 3.0 (IVF). In terms of biodistribution, the Ole-siRNA/IVF complex likely accumulates in the liver of mice. The antitumor effect of Ole-siRNA in a portal vein infusion liver-metastatic Sui67Luc tumor mouse model was evaluated using an in vivo imaging system. Ole-siRNA had a significant antitumor effect compared with nonmodified siRNA. In addition, mice with metastatic liver Sui67Luc tumors treated with Ole-siRNA showed increased survival. These results suggest that Ole-siRNAs are useful novel RNAi molecules for treating pancreatic cancer and liver metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Cell Biology, Department of Life Science, Faculty of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan.
- Division of Rare Cancer Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
- School of Pharmaceutical Sciences, Ohu University, Fukushima 963-8611, Japan.
- Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba 277-8577, Japan.
- Department of International Center for Cell and Gene Therapy, Fujita Health University, Toyoake 470-1192, Japan.
ORCID-Profile: Takanori Kubo
Förderung
- Toray Research Center
- Tsuchiya Memorial Medical Foundation
Zitieren
APA
Kubo, T., Yanagihara, K., Nishimura, Y., Iino, Y., Komatsu, T., Tansou, R., Mihara, K., & Seyama, T. (2024). Antitumor Effect of Oleoyl-siRNA against Pancreatic Cancer Using a Portal Vein Infusion Liver-Metastatic Mouse Model. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00502
Vancouver
Kubo T, Yanagihara K, Nishimura Y, Iino Y, Komatsu T, Tansou R, et al. Antitumor Effect of Oleoyl-siRNA against Pancreatic Cancer Using a Portal Vein Infusion Liver-Metastatic Mouse Model. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00502
BibTeX
@article{Kubo2024,
author = {Kubo, Takanori and Yanagihara, Kazuyoshi and Nishimura, Yoshio and Iino, Yuki and Komatsu, Teruo and Tansou, Rina and Mihara, Keichiro and Seyama, Toshio},
title = {Antitumor Effect of Oleoyl-siRNA against Pancreatic Cancer Using a Portal Vein Infusion Liver-Metastatic Mouse Model},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00502}
}
EUVIMED